Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
Chronic Central Serous Chorioretinopathy
About this trial
This is an interventional treatment trial for Chronic Central Serous Chorioretinopathy focused on measuring Chronic central serous chorioretinopathy, Ranibizumab, Photodynamic therapy
Eligibility Criteria
Inclusion Criteria:
- best-corrected visual acuity (BCVA) between 0.0 and 1.0 logarithm of the minimal angle of resolution (logMAR)
- presence of subfoveal fluid persisting for 3 months or more on optical coherence tomography (OCT)
- presence of leakage and multifocal/diffuse RPE decompensation on fluorescein angiography (FA)
- choroidal vascular hyperpermeability and abnormal dilation of choroidal vasculature on indocyanine angiography (ICGA)
Exclusion Criteria:
- previous treatment, such as laser photocoagulation, PDT, intravitreal injection of steroid or anti-VEGF agent
- evidence of choroidal neovascularization
- any other ocular diseases that could affect visual acuity
- systemic steroid treatment in the previous 12 months
- media opacity such as cataract that could interfere with adequate acquisition of OCT, FA and ICGA images
Sites / Locations
- • Department of Ophthalmology, Seoul National University College of Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Low-fluence PDT with Verteporfin
Ranibizumab
Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered